The University of Birmingham

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Children's Medical Center Corporation

Petr Illarionov

Jay A Berzofsky

Gurdyal S Besra

Masaki Terabe

Jessica J O'Konek

Dale T Umetsu

Rosemarie H De Kruyff

Ya-Jen Chang

The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived fromactivates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3Tcells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived frompartially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.

Methods for the treatment and prevention of inflammatory diseases

&#x3b2;-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of &#x3b1;-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising &#x3b2;-mannosylceramide, as well as methods of treatment of tumors are also provided.

Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

&#x3b2;-mannosylceramide and stimulation of NKT cell anti-tumor immunity

Growing community of inventors

Birmingham, United Kingdom

Petr Illarionov